Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) EBT (2016 - 2025)

Historic EBT for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to -$44.5 million.

  • Coherus Oncology's EBT rose 647.49% to -$44.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.0 million, marking a year-over-year increase of 12439.88%. This contributed to the annual value of $28.5 million for FY2024, which is 11196.41% up from last year.
  • Per Coherus Oncology's latest filing, its EBT stood at -$44.5 million for Q3 2025, which was up 647.49% from -$44.9 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's EBT peaked at $197.8 million during Q4 2024, and registered a low of -$172.9 million during Q1 2021.
  • In the last 5 years, Coherus Oncology's EBT had a median value of -$47.6 million in 2024 and averaged -$48.8 million.
  • In the last 5 years, Coherus Oncology's EBT crashed by 57376.25% in 2021 and then skyrocketed by 34833.72% in 2024.
  • Quarter analysis of 5 years shows Coherus Oncology's EBT stood at -$45.7 million in 2021, then decreased by 28.75% to -$58.9 million in 2022, then plummeted by 35.3% to -$79.7 million in 2023, then soared by 348.34% to $197.8 million in 2024, then plummeted by 122.51% to -$44.5 million in 2025.
  • Its EBT was -$44.5 million in Q3 2025, compared to -$44.9 million in Q2 2025 and -$47.4 million in Q1 2025.